🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "significant breakthrough" in the effort against increasingly resistant strains of the bacteria, according to scientists.

A Worldwide Challenge

Cases of gonorrhoea are increasing globally, with estimates suggesting over 82 million instances per year. Particularly high rates are observed in the African continent and countries within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have hit a historical peak, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary advancement in the reality of rising global incidence, increasing antimicrobial resistance and the extremely scarce treatment choices presently on offer.”

Health officials are deeply concerned about the rise in drug-resistant strains. The WHO has designated it as a "high-priority threat". A tracking program revealed that the effectiveness of standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Receive Authorization

Zoliflodacin, also known as Nuzolvence, was approved by the US FDA in mid-December for use against gonorrhoea. This infection can lead to major issues, including infertility. Experts believe that focused deployment of this new drug will help hinder the spread of drug resistance.

Gepotidacin, developed by the pharmaceutical company GSK, gained clearance in close succession. This drug, which is also used to treat UTIs, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin was the result of a unique collaborative effort for antibiotic development. The charitable organization GARDP partnered with the pharmaceutical company its industry partner to see it through.

“This authorization represents a significant shift in the management of superbug gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Testing Outcomes and Worldwide Availability

Based on findings released by a prominent scientific publication, the new drug cured more than 90% of uncomplicated infections. This puts it on an comparable level with the current standard treatment, which combines an injection and a pill. The trial included nearly 1,000 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the rights to make available and distribute the drug in numerous low-income and middle-income countries.

Clinicians on the front lines have voiced optimism. Access to a single-dose, oral treatment like this is hailed as a "game-changer" for public health efforts. This is deemed crucial to reduce the burden of the illness for individuals and to prevent the spread of extremely resistant gonorrhoea globally.